What's Happening?
Retension Pharmaceuticals has completed a $15 million Series B financing round to advance the clinical development of RTN-001, a drug for uncontrolled and resistant hypertension. The company also announced a new U.S. patent for RTN-001, extending protection through 2044. A Phase 2b trial, in collaboration with the Cleveland Clinic, is set to begin in Q4 2025, evaluating the drug's efficacy and safety in patients with hypertension.
Why It's Important?
The successful financing and patent issuance for RTN-001 highlight the potential for new treatments in the hypertension market, addressing a significant unmet need. With hypertension affecting millions of adults in the U.S., RTN-001 could offer a novel therapeutic option for patients who struggle to control their blood pressure with existing medications. The upcoming clinical trial may provide critical data to support the drug's development and eventual commercialization.
AD
